Skip to content
★ Sign in to follow
HC

Huvitz Co., Ltd. Stock: price and insider trades · South Korea

휴비츠

KR·Mcap ₩71.3BHealth Care

No insider purchase over the last 90 days. The latest, by 김현수, was filed 05 Mar 2026.

Huvitz Co., Ltd.: what insiders have been doing

This page follows insider dealings at Huvitz Co., Ltd. as filed with DART (FSS), a company from the Health Care sector. From 31 October 2025 to 31 October 2026, the disclosure feed for Huvitz Co., Ltd. logged 3 filings by 2 insiders.

Every open-market trade in the period is a purchase: 2 purchases, from 1 insider, and not a single sale. No amount is published for 2 filings, which the totals therefore leave out. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Those buying include 1 chief executive.

With 3 filings in twelve months, the company is quieter than the median of 7 filings across the 2,655 companies we follow on the same exchange. The full history, which starts in 2021, counts 9 purchases against 1 sale.

The last purchase on record was published on 5 March 2026, which is 248 days ago.

Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and UCB. These figures are compiled from regulatory filings published by DART (FSS). They describe what insiders did and are not a recommendation.

Insider Decl.
16
Thresholds
n/a
Buy Volume
€21M
9 ops. · all time
Sell Volume
€2M
1 ops. · all time

Who traded when

BuySale
김현수2 buys

Since the insiders bought

  • Filed 05 Mar 2026 · 248 days ago · €1.1M
    -24.5%
    Entry ₩8,360 · Close 30 Oct 2026 ₩6,310

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Fundamental score
Ranked 20,276 of 26,897 companies
34.1
score / 100
Value
31
Quality
38
FCF yld7.1%
Earn yld-7.0%
EV/EBITDA55.8x
ROE-1.2%
Gross mgn46%
Net mgn-4.2%
Debt/EBITDA·
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

₩6,880
Analyst consensus
·
Income statement
Revenue₩118B
Gross profit₩53.7B46% margin
EBITDA₩2.7B2% margin
Net income-₩5B-0.9% margin
Valuation
Beta0.24
Balance sheet & cash
Market cap₩71.3B
Total debt₩77.2B
Free Cash Flow₩5B
Debt / Equity69%
Profitability & ownership
ROE-1.2%
ROA1.4%
% insiders31.2%
% institutions0.7%
Last declaration on 9 March 2026
Declarations16 total
  • ●
    Executives
    Executives(filed)
    0DART
  • ▲
    Executives
    €1.1Mest.0DART
    239,580 sharesKRXDART:20260305000858
    Canonical exit: 1 Jun 2026 (T+90)
  • ▲
    대표이사Executives
    €258kest.0DART
    56,200 sharesShareKRXDART:20260305000788
    Canonical exit: 1 Jun 2026 (T+90)
  • ▼
    대량보유자Executives
    €1.5Mest.0DART
    151,000 sharesKRXDART:20240503000030
  • ●
    Executives
    Executives(filed)
    0DART
  • ▲
    대표이사Executives
    0DART
    ShareKRXDART:20231121000102
    Canonical exit: 11 Feb 2024 (T+90)
  • ▲
    Executives
    €2.6Mest.0DART
    239,580 sharesKRXDART:20231101000113
    Canonical exit: 2 Jan 2024 (T+90)
  • ▲
    Executives
    €2.4Mest.0DART
    239,580 sharesKRXDART:20231010000355
    Canonical exit: 25 Oct 2023 (T+90)
  • ▲
    Executives
    €3.0Mest.0DART
    239,580 sharesKRXDART:20230901000326
    Canonical exit: 15 Nov 2023 (T+90)
  • ▲
    Executives
    €4.0Mest.0DART
    239,580 sharesKRXDART:20230801000188
    Canonical exit: 29 Oct 2023 (T+90)
  • ▲
    Executives
    €4.0Mest.0DART
    239,580 sharesKRXDART:20230721000254
    Canonical exit: 18 Oct 2023 (T+90)
  • ▲
    Executives
    €3.9Mest.0DART
    239,580 sharesKRXDART:20230710000439
    Canonical exit: 24 Jul 2023 (T+90)
  • ●
    Executives
    Executives(filed)
    0DART
  • ●
    Executives
    Executives(filed)
    0DART
  • ●
    Executives
    Executives(filed)
    0DART
  • ●
    Executives
    Executives(filed)
    0DART

16 of 16 declarations

About Huvitz Co., Ltd.

휴비츠 is a healthcare and pharmaceutical company listed on the XKRX market. It specializes in developing innovative solutions for consumer health and wellness.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations